

HEMATOPOIETIC STEM CELLS

Hematopoietic stem cell aging and leukemia transformation

Patricia A. Colom Díaz, Jayna J. Mistry, and Jennifer J. Trowbridge

The Jackson Laboratory, Bar Harbor, ME

With aging, hematopoietic stem cells (HSCs) have an impaired ability to regenerate, differentiate, and produce an entire repertoire of mature blood and immune cells. Owing to dysfunctional hematopoiesis, the incidence of hematologic malignancies increases among elderly individuals. Here, we provide an update on HSC-intrinsic and -extrinsic factors and

processes that were recently discovered to contribute to the functional decline of HSCs during aging. In addition, we discuss the targets and timing of intervention approaches to maintain HSC function during aging and the extent to which these same targets may prevent or delay transformation to hematologic malignancies.

Introduction

Aging is a major risk factor for the development of hematologic malignancies. In 2020, blood cancers were diagnosed worldwide in more than 600 000 adults aged ≥ 65 .¹ Although not fully understood, the relationship between aging and the development of blood cancers is partly a consequence of functional decline of the hematopoietic system. Because hematopoietic stem cells (HSCs) are primarily responsible for sustaining the production of all hematopoietic and immune cells throughout life, understanding how aging affects HSCs is necessary to understand how and why hematopoietic function declines with increase in age. Much effort has focused on the comprehensive identification of the hallmarks of HSC aging, including transcriptional and epigenetic changes, altered inflammatory cytokine signaling, myeloid bias, impaired autophagy, mitochondrial dysfunction, and impaired regenerative capacity.² These HSC aging phenotypes overlap mechanistically with the processes that cause transformation and hematologic malignancy. Whether interventions to prevent HSC aging or rejuvenate the functionality of aged HSCs can effectively prevent or delay the development of leukemia remains a long-standing question. Here, we provide an updated synthesis of recent discoveries and a perspective on intervention opportunities.

HSC function in young vs middle-aged vs elderly adults

Extensive literature describes the phenotypic and functional differences between cell surface marker-defined HSCs isolated from young mice (age, 3–6 months) and old mice (age, 18–24 months), typically studied in mice of a C57BL/6 inbred strain background. These studies reported that old HSCs have impaired hematopoiesis,³ myeloid bias at the transcriptome and functional levels,⁴ dysfunctional mitochondria,⁵ decreased

polarity of Cdc42,⁶ increased reactive oxygen species (ROSs),⁷ increased γ H2AX caused by ineffective H2AX dephosphorylation rather than sustained DNA damage,⁸ altered DNA methylation,⁹ changes in histone modification patterns¹⁰ (which are also observed in aged human hematopoietic stem and progenitor cells [HSPCs]),¹¹ and increased transformation to leukemia.² An important nuance revealed by single-cell transplantation assays and inducible lineage tracing systems is that old mice contain a greater number of functional HSCs compared with young mice, although on a per HSC basis, they have reduced mature hematopoietic cell output.^{12,13} Recently, integrative analysis of transcriptome and chromatin accessibility of old HSCs revealed selective accessibility of enhancers with stress-responsive transcription factor motifs, suggesting chronic or historical exposure to external stress may be inscribed at an epigenetic level in old HSCs.¹⁴

Whether the aforementioned numerous alterations coincide or occur in a particular order or sequence over time and age is unknown because longitudinal studies collecting phenotypic data on a cohort of animals, from young adulthood into old age, have yet to be reported. We can glean insights from cross-sectional studies, including the midage point(s) between young and old animals. Many phenotypes considered to be hallmarks of aged hematopoiesis are observed in C57BL/6 mice at 9 or 12 months of age,¹⁵ estimated to be equivalent to ~37 to 47 years for humans¹⁶ (Figure 1). These phenotypes include increased frequency and number of cell surface marker-defined HSCs and myeloid bias in the HSC compartment and have been described in both mice and humans.^{15,17} These observations are consistent with the mathematical modeling of hematopoietic aging within C57BL/6 mice from young age (10–16 weeks old) to middle age (40–54 weeks old).¹⁸ This approach found a rapid decrease in the ratio of short-term HSCs to long-term HSCs during middle age that remained constant into old age




Figure 1. Phenotypic alterations in adult HSCs with increasing age in C57BL/6 mice and humans. *Supporting studies in mice and humans. [#]Supporting studies in mice. Illustration created using BioRender.com.

(>86 weeks old),¹⁸ suggesting impairment in the first steps of differentiation from HSCs to their progeny approximately at middle age. A stress signaling pathway mediated by p38MAPK, known to be activated in old mouse HSCs,⁷ was also recently found to be more active in middle-aged HSCs than in younger HSCs.¹⁹ In humans, HSCs isolated from middle-aged individuals (42-61 years old) have increased expression of aging-associated myeloid lineage genes such as *P-selectin (SELP)* and *HOXA9* compared with that in young individuals.¹⁷ Although there are many molecular similarities between middle-aged HSCs and old HSCs, transplantation experiments using mouse models have revealed that middle-aged HSCs, but not old HSCs, can be functionally rejuvenated by a young bone marrow (BM) microenvironment.²⁰ This work suggests that there may be a therapeutic window of opportunity at or before middle age to effectively intervene to prevent functional HSC decline, which is discussed in detail later in this review.

Aging-associated CH: friend or foe?

Age-associated clonal hematopoiesis (CH) is a natural consequence of somatic mutations in the human hematopoietic stem and/or progenitor cells. A subset of acquired somatic mutations can confer a selective advantage to HSCs and their progeny such that they clonally expand and become overrepresented within the total pool of hematopoietic cells. The most common mutations found in human CH are the epigenetic regulatory genes *DNA methyltransferase 3a (DNMT3A)*, *Tet methylcytosine dioxygenase 2 (TET2)*, and *additional sex combs like 1 (ASXL1)*.^{21,22} Although CH is not a disease, it is associated with a modestly enhanced risk of hematologic malignancy.²¹ Using genetically engineered mouse models, the functions of *DNMT3A*, *TET2*, and *ASXL1* in HSCs and hematopoiesis have been well described.²³⁻²⁵ However, the manner and reason for human hematopoietic cells with these mutations to undergo positive selection during aging, leading to clonal expansion and

leukemic transformation remains to be determined. Some hints have emerged regarding the relevant mechanisms from related studies, using stress and inflammation as selective pressures.

Allogeneic HSC transplantation is a context in which, the impact of stress on CH can be directly studied in humans by comparing donors and recipients. Recent reports have found a larger clone size in transplantation recipients with donor-engrafted CH than that in donors.^{26,27} Similarly, in C57BL/6 mice, mutations in recurrent human CH genes were detectable only after transplantation.²⁸ Together, these data support that transplantation stress contributes to positive clonal selection/expansion. Importantly, the latter study suggests that the lifetime of healthy laboratory mice is not sufficient to allow most clones with mutations in human CH-relevant genes to expand to a level detectable via the current methodology.²⁸ Although this may preclude modeling of human CH in aging wild-type C57BL/6 mice, it does support the study of aging mice with genetically engineered human CH mutations to reveal mechanisms relevant to humans.

Studies using *Mycobacterium avium* infection of genetically engineered *Dnmt3a*-mutant mouse models have found that interferon gamma-mediated inflammation promotes expansion of *Dnmt3a*-mutant HSCs.²⁹ Tumor necrosis factor α (TNF- α) also promotes the selective advantage of mouse *Dnmt3a*-mutant HSCs, and specific targeting of TNF receptor 1 but not TNF receptor 2 selectively impaired *Dnmt3a*-mutant HSC fitness.³⁰ TNF- α has also been found to favor mouse *Tet2*-mutant hematopoiesis.³¹ Not only do CH-mutant HSCs have differential responses to proinflammatory cytokine signaling, new work also suggests that CH-mutant hematopoietic cells can induce and maintain a proinflammatory state. In a zebrafish model of a human *ASXL1* mutation, mature mutant myeloid cells produce proinflammatory cytokines, whereas mutant HSPCs remain resistant to this inflammatory environment via the expression of

immunomodulatory genes.³² Inflammation also affects the transformation of CH to hematologic malignancy. In *Tet2*-mutant mice, activation of inflammatory signaling is an essential trigger of chronic myelomonocytic leukemia-like disease.³¹ Together, literature primarily using mouse models supports the concept that inflammatory processes provide selective pressure favoring survival of HSPCs with CH mutations, leading to clonal expansion and contributing to transformation to hematologic malignancies. This will need to be critically evaluated in future human studies. Because chronic low-grade elevation of circulating proinflammatory cytokines has been widely reported during aging,³³ this is a potential mechanistic link between aging, CH, and hematologic malignancy.

The risks and benefits of age-associated CH continue to be explored. CH has been associated with an increased risk of nonhematologic diseases, such as atherosclerosis³⁴ and osteoporosis.³⁵ In contrast, evidence supports that specific CH mutations may enhance adaptive immune cell functionality. For example, improved overall survival and reduced risk of relapse after BM transplantation were reported in transplantation recipients of *DNMT3A*-mutant donor hematopoietic cells,³⁶ which could be related to the enhanced function of *DNMT3A*-mutant T lymphoid cells discovered in mouse

models.³⁷ Dissecting mechanisms by which CH can have a protective benefit in the context of certain diseases yet accelerate or positively contribute to the development of others, particularly within the hematopoietic system, will be critical in considering appropriate intervention strategies.

Update on HSC-intrinsic mechanisms causing hematopoietic aging and initiation of hematologic malignancies

Here, we provide an update on recent literature and emerging genes and mechanisms responsible for HSC aging and hematologic malignancy initiation (Table 1).

An integrative analysis of 16 distinct transcriptomics studies of murine HSC aging from different research groups worldwide has provided a unified perspective on aged HSCs and a centralized resource for the field.³⁸ This work has identified altered expression of genes in physiological HSC aging, including *Selp*, *nuclear protein 1*, *Semaphorin 4a* (*Sema4a*), and *Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain 2* (*Cited2*). *Selp* expression at the transcriptional and protein levels in old HSCs has been found to

Table 1. Genes and processes recently revealed to have roles in both HSC aging and transformation

Gene	Expression in old vs young HSCs	HSC phenotype	Hematologic malignancy phenotype	Function
<i>Selp</i>	HSC aging (RNA and protein ³⁸)	Knockout increases hematopoietic regeneration ³⁹	Knockout accelerates leukemogenesis in CML ^{39,40}	Cell adhesion molecule produced by platelets and endothelial cells for leukocyte adhesion ³⁸
<i>Nupr1</i>	HSC aging (RNA ³⁸)	Knockout increases HSC quiescence and engraftment potency ⁴¹	Targeted inhibition reduces the growth of AML, T-cell ALL, lymphoma, and multiple myeloma cell lines ^{42,43}	High-mobility group protein family member involved in apoptosis, stress response, and cancer progression ⁴¹
<i>Sema4a</i>	HSC aging (RNA ³⁸)	Knockout increases myeloid-biased HSC proliferation and impairs regenerative capacity ⁴⁴	Knockout impairs multiple myeloma cell growth ⁴⁵	Binds to surface receptor Plexin-D1, essential for HSC self-renewal and protection from stress ⁴⁴
<i>Cited2</i>	HSC aging (RNA ³⁸)	Knockout depletes functional HSCs in young mice ⁴⁶	Knockdown decreases AML pathogenesis and induces apoptosis ⁴⁷	Binding partner of the acetyltransferase CBP/p300 in transcriptional regulation ⁴⁶
<i>Hsf1</i>	HSC aging (protein ⁴⁸)	Dispensable in young HSCs; knockout impairs hematopoietic regeneration by middle age ⁴⁸	Knockout impairs initiation and maintenance of AML and T-cell ALL ^{49,50}	Maintains proteostasis and self-renewal in response to stress ⁴⁸
<i>Igf2bp2</i>	HSC aging (RNA ⁵¹)	Knockout impairs HSC function in young mice ⁵¹	Knockdown inhibits the growth of AML cell lines ⁵²	RNA-binding protein that regulates messenger RNA stability and translation ⁵¹
<i>Egr1</i>	HSC aging (RNA ⁵³)	Knockout increases HSC cycling and mobilization ⁵⁴	Tumor suppressor in ALL, CML, and AML ⁵⁵	Transcription factor that regulates cell growth, differentiation, and depolarization ⁵⁵
<i>Twist1</i>	HSC aging (RNA ⁵⁶)	Knockout reduces HSC self-renewal and causes myeloid-biased hematopoiesis ⁵⁶	Knockdown reduces AML cell line proliferation and sensitizes to decitabine ⁵⁷	Transcription factor essential for embryonic mesoderm development ⁵⁶
<i>Gata2</i>	No change (RNA ³⁸)	Haploinsufficiency promotes HSC proliferation and functional decline ⁵⁸	Haploinsufficiency causes long latency but aggressive MDS and AML ⁵⁹	Essential transcription factor for fetal and adult hematopoiesis ⁶⁰

contribute to myeloid-biased hematopoiesis and HSC activation phenotypes.³⁸ In a BCR/ABL-induced chronic myelogenous leukemia (CML) model, knockout of *Selp* accelerated leukemogenesis, increased cell surface marker-defined leukemia stem cells, and altered adhesion of myeloid progenitors to the marrow stroma.^{39,40} Taken together, more studies are needed to fully elucidate the contribution of SELP^{hi} vs SELP^{lo} old HSCs to leukemogenesis and to determine whether fine-tuning levels of *Selp* would facilitate the rejuvenation of old HSCs without increasing susceptibility to hematologic malignancies.

Nupr1, encoding a stress response factor, is elevated at the transcript level in old HSCs. In young mice, conditional knockout of *Nupr1* caused HSCs to exit quiescence and conferred a competitive repopulation advantage.⁴¹ In hematologic malignancy, *Nupr1* is significantly higher in multiple myeloid cell lines and primary multiple myeloid BM samples than in healthy BM, and short hairpin RNA knockdown of *Nupr1* resulted in reduced proliferation, induction of apoptosis, and arrest of cell cycle.⁴² A modified small molecule capable of targeting NUPR1 has shown dose-dependent growth inhibition of multiple cancer cell lines, including acute myeloid leukemia (AML) (THP-1), lymphoma (Daudi), and acute T-cell leukemia (Jurkat).⁴³ Further investigation is needed to determine whether *Nupr1* is an effective target to both deplete dysfunctional old HSCs and inhibit hematologic malignancy.

Sema4a is elevated at the transcript level in old HSCs. In a recent nonpeer-reviewed preprint, knockout of *Sema4a* resulted in proliferation and expansion of myeloid-biased HSCs at the expense of their regenerative capacity.⁴⁴ Surprisingly, this was noncell-autonomous because the transplantation of wild-type myeloid-biased HSCs into *Sema4a*-deficient recipient mice also resulted in excessive proliferation and engraftment failure in the long term. In hematologic malignancy, cell surface expression of SEMA4A was found to be essential for myeloma cell growth, and a potent antibody-drug conjugate has been engineered for therapeutic targeting of myeloma based on SEMA4A expression.⁴⁵ Further studies will be critical to define *Sema4a*-cell context dependencies for aging and malignancies, both with hematopoietic and nonhematopoietic cell fractions of the BM, to assess the potential therapeutic index for SEMA4A targeting.

Levels of *Cited2*, encoding a binding partner of the acetyltransferase CBP/p300, are also elevated in old HSCs at the transcript level. Knockout of *Cited2* in young mice reduced HSCs but had no effect on steady-state hematopoiesis.⁴⁶ Mice survived normally, and the HSC pool failed to expand upon aging. In contrast, *Cited2* is necessary for the functional regenerative capacity after HSC transplantation. In hematologic malignancies, RNA interference-mediated knockdown of *Cited2* in AML cell lines decreased their pathogenicities in vivo and increased apoptosis.⁴⁷ Taken together, targeting *Cited2* in steady-state hematopoiesis may prevent the expansion of phenotypic HSCs with aging and achieve selective targeting of AML.

Heat shock factor 1 (Hsf1) levels increased in old HSCs at the protein level, maintain proteostasis and are critical for HSC

regenerative capacity.⁴⁸ A similar function for *Hsf1* has been recently reported in AML. Deletion of *Hsf1* reduced the initiation and maintenance of murine *MLL-AF9*-induced AML, and knockdown or small molecule inhibition of *HSF1* reduced the growth of primary human AML cells.⁴⁹ Because nuclear *HSF1* expression is increased in human AML samples relative to that in healthy BM controls and is correlated with disease status, it has been suggested to be used as a biomarker as well as a therapeutic target.⁴⁹ This is consistent with elevated *Hsf1* in T-cell acute lymphoblastic leukemia (ALL), in which *Hsf1* ablation was found to suppress the growth of both mouse and human T-cell ALL cells.⁵⁰ A multitude of small molecules and naturally derived compounds to inhibit HSF1 have been developed, but most show off-target effects, precluding further clinical testing.⁶¹ Additional studies are needed to determine whether HSC rejuvenation strategies can reduce the dependence of old HSCs on *Hsf1*, or whether a sufficient therapeutic window exists between the reliance of malignant and healthy, old HSCs on *Hsf1*, enabling this to be a targetable factor in the treatment of hematologic malignancies.

In old HSCs, *Igf2bp2* has been found to be decreased in expression at the transcript level.⁵¹ *Igf2bp2* encodes an RNA-binding protein that regulates messenger RNA stability and translation. The role of *Igf2bp2* in HSC aging is multifaceted. In younger individuals, *Igf2bp2* contributes to aging-associated HSC expansion and myeloid lineage bias, whereas age-related loss of *Igf2bp2* impairs the growth and repopulation capacity of old HSCs.⁵¹ *Igf2bp2*-deficient mice did not exhibit aging-associated phenotypes, such as increase in phenotypic HSCs or myeloid-biased hematopoiesis. Notably, *IGF2BP2* is found to be increased in expression in adult AML, and such increased expression is associated with poor prognosis.⁵² Together, despite a natural decline in *Igf2bp2* levels in old HSCs, targeting this molecule could achieve beneficial effects with respect to reducing old HSC attributes and their transformation into hematologic malignancies.

The transcriptional factors *early growth response factor 1 (Egr1)*, *Twist-related protein 1 (Twist1)*, and *Gata binding protein 2 (Gata2)* have also recently been implicated, or reimplicated, in HSC aging and transformation. *Egr1*, an immediate-early response transcription factor, is increased in expression in old HSCs.⁵³ Mice lacking *Egr1* have expansion in steady-state levels of cycling HSCs and spontaneous mobilization.⁵⁴ In contrast, in a variety of studies conducted for human AML, chronic lymphocytic leukemia, and ALL cell lines, *EGR1* has been identified as a tumor suppressor.⁵⁵ *Twist1*, an essential regulator of mesoderm development, is increased in old HSCs, at the transcript level. Unexpectedly, *Twist1* knockout mice have been reported exhibit aging-associated phenotypes of reduced HSC self-renewal and myeloid-biased hematopoiesis.⁵⁶ In AML cell lines, knockdown of *TWIST1* was found to reduce proliferation and increase sensitivity to the hypomethylating agent decitabine.⁵⁷ *Gata2*, known to be essential for proliferation, maintenance, and function of HSCs, is not reported to be altered in transcript expression with aging. In hematologic malignancy, overexpression of *GATA2* is observed in myelodysplastic syndrome (MDS) and AML.⁶⁰ In addition, gain-of-function mutations in *GATA2* are correlated with poor prognosis in CML.⁵⁹ In contrast, individuals with germ line or acquired *GATA2*

haploinsufficiency also have a high propensity to develop MDS or AML, typically preceded by immunodeficiency. A recent report provides evidence that *Gata2* haploinsufficiency in mice exacerbates the decline in HSC function and decreases lymphoid progenitor cell production during aging,⁵⁸ providing a mechanistic link between aging and propensity for the transformation. In an independent study, *Gata2* haploinsufficiency was found to delay leukemia onset in a mouse model of human *inv(16)* AML (*Cbfb-MYH11* knock in) but paradoxically resulted in a more aggressive leukemia phenotype.⁶² Taken together, these data suggests that *Egr1*, *Twist1*, and *Gata2* may not be ideal targets for effective intervention strategies based on their complex roles.

Update on HSC-extrinsic mechanisms causing hematopoietic aging and leukemia initiation

Numerous changes have been described in aging BM microenvironments, including vascular remodeling, BM mesenchymal stromal cell dysfunction, altered adrenergic signaling, proinflammatory cytokine production, and frequent senescence.⁶³ The aging BM microenvironment can induce HSC aging phenotypes and contribute to the pathogenesis of hematologic malignancies. Moreover, leukemia cells can remodel the BM microenvironment and accelerate aging phenotypes in a feed-forward loop. Here, we provide an update on the recent literature in this area.

Acute and chronic inflammation

Inflammation influences both HSCs and the BM microenvironment, and increasing evidence suggests that this can permanently change the HSC pool. Young adult mice exposed to acute inflammatory challenges show accelerated HSC aging and impaired hematopoietic regeneration capacity.⁶⁴ Increased levels of interleukin 1 β (IL-1 β) produced by old and damaged endosteum⁶⁵ reduces HSC self-renewal⁶⁶ and increases myeloid cell proliferation.⁶⁷ Pharmacologic inhibition of IL-1 mitigates myeloid-biased hematopoietic output from HSCs,⁶⁷ reverses deterioration of the aging BM microenvironment, and restores HSC regenerative function.⁶⁵ In contrast, pharmacologic inhibition of IL-6 increases the frequency and functionality of aging erythroid progenitor cell populations rather than directly affecting aging HSCs.⁶⁸ This observation highlights that pharmacologic strategies to broadly ameliorate hematopoietic aging phenotypes may require an expanded viewpoint to replenish critical factors for both HSC and progenitor cell function.

Chronic inflammation has been shown to promote the growth of mutant HSC clones, leading to leukemic transformation. Proinflammatory IL-6 signaling drives progression of MDS to AML, and the knockout of IL-6 was sufficient to extend survival in murine models.⁶⁹ Increased IL-1 β predicts poor prognosis in CML, and inhibition of IL-1 signaling in combination with a tyrosine kinase inhibitor enhanced targeting of CML stem cells.⁷⁰ IL-1 has also been shown to affect disease progression in AML through p38MAPK.⁷¹ Together, this work suggests an intriguing possibility that persistent exposure to inflammation early in adulthood may influence the process and timing of aging HSC phenotypes, and continuous elevation of

inflammation later in life may increase the susceptibility to hematologic malignancies.

The gut microbiome is a source of inflammatory signaling that affects hematopoiesis and HSC function. In old germ-free mice, the HSC pool remains lineage balanced compared with specific pathogen-free mice with expanded myeloid-biased HSCs.⁷² Old mice have increased levels of microbial compounds stimulating IL-1 production,⁶⁷ which reduces HSC self-renewal and increases myeloid cell proliferation, as described earlier. Fecal microbiota transplantation from young mice into old mice rejuvenated HSC function, mitigated inflammatory signaling, and restored lymphoid differentiation capacity of aging HSCs.⁷³ In young mice genetically predisposed to develop precursor B-cell ALL, antibiotic treatment accelerates leukemia development.⁷⁴ Antibiotic treatment also accelerates leukemia development in a mouse model of AML driven by *MLL-AF9*, which can be reversed by fecal microbiota transplantation.⁷⁵ Autologous fecal microbiota transfer has been shown to be safe in patients with AML in a recent phase 2 clinical trial.⁷⁶ These observations supports alterations in gut microbiota and intestinal barrier damage during aging dysregulates HSC function and provides a therapeutic option for restoring HSC function and preventing hematologic malignancies.

BM microenvironment senescence

Senescent cells accumulate with aging, and recent evidence suggests that senescence can be induced throughout the body of young mice by the transfer of blood from old mice.⁷⁷ In the BM microenvironment, senescent cells have been found to directly affect HSC function. In a model of induced senescence, *Terc* knockout BM stromal cells (BMSCs) impair HSC functional regenerative capacity and accelerate myelopoiesis.⁷⁸ Aging human BMSCs have been found to impair the clonogenic potential of young human CD34⁺ HSPCs and induce a proinflammatory gene expression program.⁷⁹ Interventions targeting senescent cells using senolytics have shown effects on both nonhematopoietic and hematopoietic cells within the BM microenvironment. An important nuance is that senescence has been shown not to be a major mechanism intrinsically regulating HSC aging,⁸⁰ therefore, studies targeting senescence in the rejuvenation of HSC function are likely to occur through non-cell-autonomous mechanisms. For example, aging mice treated with the senolytic drug ABT263 (Navitoclax) induced apoptosis of HSCs and non-HSCs, expressing markers of senescence and resulting in rejuvenated HSC function.⁸¹ In addition, a senolytic cocktail of dasatinib and quercetin has recently been shown to improve the osteogenic capacity of aging BMSCs *in vitro* and *in vivo*,⁸² which has the potential to improve aging HSC function in a non-cell-autonomous manner.

In hematologic malignancy, AML cells have been shown to contribute to the induction of BMSC senescence, and the resulting senescence-associated secretory phenotype promotes leukemia proliferation and survival.⁸³ Targeting the senescent microenvironment by deleting p16INK4a-expressing BMSCs slows AML progression and extends survival.⁸³ Because the senescent microenvironment appears to be a vital component in the progression of hematologic malignancy, it warrants further investigation for therapeutic intervention.

Adipogenesis and metabolic changes in the BM microenvironment

BM adipocyte tissue volume increases with aging in humans.⁸⁴ In mouse models, assessments of adipocyte abundance with aging show varying conclusions, and this abundance may be influenced by diet.^{65,85,86} A further dissent in the field is with respect to the role of BM adipocytes in regulating HSC function. Multiple studies have suggested that increased mature adipocytes negatively regulate HSC number and function.^{86,87} Although accumulation of BM adipocytes due to the loss of Bmi1 expression was reported to reduce HSC proliferation and number, these alterations were insufficient to broadly cause HSC aging phenotypes,⁸⁸ suggesting that they may cooperate with other aging-associated changes in the BM microenvironment, causing a decline in HSC function. In contrast, a distinct report has robustly determined that adipocytes are a critical source of stem cell factors required to support hematopoietic regeneration. Deletion of *Scf* using an Adipoq-Cre/ER mouse model impaired hematopoietic regeneration, depleted HSCs, and reduced mouse survival after irradiation or 5-fluorouracil treatment.⁸⁹ Before moving toward therapeutic intervention, further studies are needed to clarify the effect of adipocyte populations on HSC function in distinct contexts of steady-state, regenerative, and aging hematopoiesis.

Age-related adipocyte expansion clearly plays a role in the promotion of hematologic malignancies. ALL cells have been shown to use free fatty acids released from adipocytes as a fuel source to enhance leukemia progression.⁹⁰ Additionally, AML cells stimulate lipolysis of BM adipocytes to release free fatty acids taken up by blast cells. This process enhances AML proliferation by increasing mitochondrial fatty acid β -oxidation.⁹¹ Leukemia cells use mitochondrial respiration to meet their metabolic demands, and inhibition of amino acid metabolism by venetoclax can target human leukemia stem cells and is effective in combination with azacytidine for extending survival in patients with AML.⁹²⁻⁹⁴ It has been reported that human AML generates reduced NAD phosphate oxidase to promote mitochondrial transfer from BMSCs to AML cells through tunneling nanotubes.⁹⁵ Recent studies have shown that inhibiting this mitochondrial transfer decreases AML metabolic capacity and inhibits leukemia proliferation.^{96,97}

New insights into therapeutic interventions for hematopoietic aging: is rejuvenation of aged HSCs possible?

Recent literature generated by independent groups strongly supports that HSCs in old mice resist functional rejuvenation by circulating factors present in young blood.^{20,98} Old HSCs did not show functional rejuvenation upon plasma transfer from young animals, caloric restriction, exercise, parabiosis with young animals,⁹⁸ or transplantation into unconditioned young recipient mice.²⁰ Surprisingly, transplantation into unconditioned young recipient mice restored the transcriptome, but not DNA methylation patterns, in old HSCs such that they closely resemble young HSCs.²⁰ This suggests a disconnect between transcriptional, epigenetic, and functional rejuvenation at the HSC level. In addition to DNA methylation,²⁰ HSCs in old mice have posttranscriptional alterations in autophagy and metabolism,⁹⁹ micro RNA regulation, protein translation,¹⁰⁰ and

proteostasis,⁴⁸ which represent potential mechanisms by which old HSCs are not functionally restored despite the reset transcriptional profiles. Of the remaining transcriptional signatures that were not restored upon transplantation of old HSCs into young recipient mice, these were enriched for proteasome, calcium ion transport, and specific metabolic (phosphate and phosphorus) processes,²⁰ further pointing to specific processes that may be essential for functional rejuvenation.

In contrast to old HSCs, transplantation of HSCs from middle-aged donor mice into young mice could, in part, functionally rejuvenates middle-aged HSCs.²⁰ Our group has performed transcriptional comparisons between middle-aged and old C57BL/6 HSCs and have found key differences, including that middle-aged HSCs have higher fatty acid metabolism, oxidative phosphorylation, and ribosomal protein translation initiation and less inflammatory signaling (mediated by TNF α , IL-6, and interferon gamma, IL-2), myeloid transcriptional network activation, and ROS signatures compared with old HSCs.¹⁵ Upon examining hematopoietic-extrinsic contributions toward aging and rejuvenation, reduction of insulin-like growth factor 1 in the middle-aged BM microenvironment causes HSCs aging phenotypes, including myeloid bias and expansion of phenotypic HSCs.¹⁵ Stimulation of middle-aged HSCs with insulin-like growth factor 1 expanded lymphoid-biased HSCs and restored lymphoid cell output from HSCs.¹⁵ In addition, a report describing the use of mitoquinol to enhance the mitochondrial membrane potential of aged HSCs found that supplementing drinking water of mice, starting at middle age (14 months old), delayed the onset of myeloid-biased hematopoiesis, prevented the onset of anemia, and reduced phenotypic HSC expansion over a 5-month period.¹⁰¹ Taken together, targeting HSCs at middle age may be a window of opportunity for rejuvenation. Beyond the transcriptome, investigation of biomarkers of functional HSC rejuvenation is needed to enable high-throughput screening approaches and clinical assessment of the success of rejuvenation factors.

The question "can interventions to prevent HSC aging or rejuvenate the functionality of aged HSCs effectively prevent or delay the development of leukemia?" remains unanswered. However, recent findings of HSC-intrinsic and -extrinsic mechanisms contributing to hematopoietic aging and leukemogenesis (Figure 2) provide compelling potential intervention mechanisms, including targeting the proteasome and translational processes, resetting metabolism and chromatin/epigenome patterning, chronic inflammation, senescence, and senescence-associated secretory phenotype.

Emerging research directions to pursue in HSC aging and hematologic malignancy

In a forward-thinking manner of emerging research directions, intriguing new findings that HSCs express major histocompatibility complex II, act as antigen-presenting cells to protect the integrity of the HSC pool, and delay the development of leukemia¹⁰² have revealed new biological aspects to be explored during aging. If the antigen-presentation capacity is compromised in aging HSCs, restoring this capacity could be a valuable therapeutic strategy to decrease the risk of hematologic malignancies, in the context of aging.




Figure 2. Potential targetable mechanisms to rejuvenate aged HSCs and prevent hematologic malignancy. Phenotypes and biological mechanisms implicated in HSC aging, hematologic malignancy, or both are shown on the left. As overlapping mechanisms represent the most compelling targets for intervention, the inset table outlines the potential targetable mechanisms discussed in detail in this review. Illustration created using BioRender.com.

It has very recently been discovered that macrophages groom the HSC compartment during development, depleting HSCs high in ROSs, and stimulating proliferation and expansion of HSCs passing through this checkpoint.¹⁰³ During aging, HSCs with high ROSs accumulate and are associated with myeloid-biased hematopoiesis.¹⁰⁴ Exploring HSC grooming in adults and the elderly may open new avenues of exploration and intervention or rejuvenation strategies.

A historical challenge in this field is in the translation of the findings from animal models into human interventions. The development of an innovative new human BM organoid platform from induced pluripotent stem cells enables healthy and malignant human hematopoietic cell engraftment and survival.¹⁰⁵ The adaptation of this technology offers a means to evaluate the efficacy of small molecules or other therapeutic strategies in the prevention or reversal of human HSC aging phenotypes and transformation to malignancy.

Acknowledgments

The authors thank the members of Trowbridge laboratory for their helpful discussions and critical comments.

This work was supported by National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases grant R01DK118072 (J.J.T.) and NIH National Institute on Aging grants R01AG069010 and U01AG077925 (J.J.T.). J.J.T. is a Scholar of the Leukemia & Lymphoma Society. J.J.M. is supported by a scholar award from The Jackson Laboratory.

Authorship

Contribution: All authors wrote and edited the manuscript.

Conflict-of-interest disclosure: J.J.T. receives royalties for patent licensing from Fate Therapeutics. The remaining authors declare no competing financial interests.

ORCID profile: P.A.C.D., 0000-0001-5195-3408.

Correspondence: Jennifer J. Trowbridge, The Jackson Laboratory, 600 Main St, Bar Harbor, ME 04609; email: jennifer.trowbridge@jax.org.

Footnote

Submitted 23 November 2022; accepted 8 February 2023; pre-published online on *Blood* First Edition 17 February 2023. <https://doi.org/10.1182/blood.2022017933>.

REFERENCES

- Soto-Perez-de-Celis E, Martínez-Peromingo J, Chávarri-Guerra Y, et al. Implementation of geriatric haematology programmes for the treatment of older people with haematological malignancies in low-resource settings. *Lancet Healthy Longev*. 2021;2(11):e754-e763.
- Verovskaya EV, Dellorusso PV, Passequé E. Losing sense of self and surroundings: hematopoietic stem cell aging and leukemic transformation. *Trends Mol Med*. 2019; 25(6):494-515.
- Busch K, Klapproth K, Barile M, et al. Fundamental properties of unperturbed haematopoiesis from stem cells in vivo. *Nature*. 2015;518(7540):542-546.
- Rossi DJ, Bryder D, Zahn JM, et al. Cell intrinsic alterations underlie hematopoietic stem cell aging. *Proc Natl Acad Sci U S A*. 2005;102(26):9194-9199.
- Norddahl GL, Pronk CJ, Wahlestedt M, et al. Accumulating mitochondrial DNA mutations drive premature hematopoietic aging phenotypes distinct from physiological stem cell aging. *Cell Stem Cell*. 2011;8(5): 499-510.
- Florian MC, Klose M, Sacma M, et al. Aging alters the epigenetic asymmetry of HSC division. *PLoS Biol*. 2018;16(9):e2003389.
- Ito K, Hirao A, Arai F, et al. Reactive oxygen species act through p38 MAPK to limit the

- lifespan of hematopoietic stem cells. *Nat Med*. 2006;12(4):446-451.
8. Flach J, Bakker ST, Mohrin M, et al. Replication stress is a potent driver of functional decline in ageing haematopoietic stem cells. *Nature*. 2014;512(7513):198-202.
 9. Beerman I, Bock C, Garrison BS, et al. Proliferation-dependent alterations of the DNA methylation landscape underlie hematopoietic stem cell aging. *Cell Stem Cell*. 2013;12(4):413-425.
 10. Sun D, Luo M, Jeong M, et al. Epigenomic profiling of young and aged HSCs reveals concerted changes during aging that reinforce self-renewal. *Cell Stem Cell*. 2014;14(5):673-688.
 11. Adelman ER, Huang HT, Roisman A, et al. Aging human hematopoietic stem cells manifest profound epigenetic reprogramming of enhancers that may predispose to leukemia. *Cancer Discov*. 2019;9(8):1080-1101.
 12. Yamamoto R, Wilkinson AC, Ooehara J, et al. Large-scale clonal analysis resolves aging of the mouse hematopoietic stem cell compartment. *Cell Stem Cell*. 2018;22(4):600-607.e4.
 13. Säwen P, Eldeeb M, Erlandsson E, et al. Murine HSCs contribute actively to native hematopoiesis but with reduced differentiation capacity upon aging. *eLife*. 2018;7:e41258.
 14. Itokawa N, Oshima M, Koide S, et al. Epigenetic traits inscribed in chromatin accessibility in aged hematopoietic stem cells. *Nat Commun*. 2022;13(1):2691.
 15. Young K, Eudy E, Bell R, et al. Decline in IGF1 in the bone marrow microenvironment initiates hematopoietic stem cell aging. *Cell Stem Cell*. 2021;28(8):1473-1482.e7.
 16. SanMiguel JM, Young K, Trowbridge JJ. Hand in hand: intrinsic and extrinsic drivers of aging and clonal hematopoiesis. *Exp Hematol*. 2020;91:1-9.
 17. Pang WW, Price EA, Sahoo D, et al. Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age. *Proc Natl Acad Sci U S A*. 2011;108(50):20012-20017.
 18. Klose M, Florian MC, Gerbaulet A, Geiger H, Glauche I. Hematopoietic stem cell dynamics are regulated by progenitor demand: lessons from a quantitative modeling approach. *Stem Cells*. 2019;37(7):948-957.
 19. Sorimachi Y, Karigane D, Ootomo Y, et al. p38 α plays differential roles in hematopoietic stem cell activity dependent on aging contexts. *J Biol Chem*. 2021;296:100563.
 20. Kuribayashi W, Oshima M, Itokawa N, et al. Limited rejuvenation of aged hematopoietic stem cells in young bone marrow niche. *J Exp Med*. 2021;218(3):e20192283.
 21. Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. *N Engl J Med*. 2014;371(26):2477-2487.
 22. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. *N Engl J Med*. 2014;371(26):2488-2498.
 23. Challen GA, Sun D, Jeong M, et al. Dnmt3a is essential for hematopoietic stem cell differentiation. *Nat Genet*. 2011;44(1):23-31.
 24. Li Z, Cai X, Cai C-L, et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. *Blood*. 2011;118(17):4509-4518.
 25. Abdel-Wahab O, Gao J, Adli M, et al. Deletion of Asx1 results in myelodysplasia and severe developmental defects in vivo. *J Exp Med*. 2013;210(12):2641-2659.
 26. Boettcher S, Wilk CM, Singer J, et al. Clonal hematopoiesis in donors and long-term survivors of related allogeneic hematopoietic stem cell transplantation. *Blood*. 2020;135(18):1548-1559.
 27. Wong WH, Bhatt S, Trinkaus K, et al. Engraftment of rare, pathogenic donor hematopoietic mutations in unrelated hematopoietic stem cell transplantation. *Sci Transl Med*. 2020;12(526):eaax6249.
 28. Chin DWL, Yoshizato T, Virding Culleton S, et al. Aged healthy mice acquire clonal hematopoiesis mutations. *Blood*. 2022;139(4):629-634.
 29. Hormaechea-Agulla D, Matatal KA, Le DT, et al. Chronic infection drives Dnmt3a-loss-of-function clonal hematopoiesis via IFN γ signaling. *Cell Stem Cell*. 2021;28(8):1428-1442.e6.
 30. SanMiguel JM, Eudy E, Loberg MA, et al. Distinct tumor necrosis factor alpha receptors dictate stem cell fitness versus lineage output in Dnmt3a-mutant clonal hematopoiesis. *Cancer Discov*. 2022;12(12):2763-2773.
 31. Abegunde SO, Buckstein R, Wells RA, Rauh MJ. An inflammatory environment containing TNF α favors Tet2-mutant clonal hematopoiesis. *Exp Hematol*. 2018;59:60-65.
 32. Avagyan S, Henninger JE, Mannherz WP, et al. Resistance to inflammation underlies enhanced fitness in clonal hematopoiesis. *Science*. 2021;374(6568):768-772.
 33. Fulop T, Witkowski JM, Olivieri F, Larbi A. The integration of inflammaging in age-related diseases. *Semin Immunol*. 2018;40:17-35.
 34. Jaiswal S, Natarajan P, Silver AJ, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. *N Engl J Med*. 2017;377(2):111-121.
 35. Kim PG, Niroula A, Shkolnik V, et al. Dnmt3a-mutated clonal hematopoiesis promotes osteoporosis. *J Exp Med*. 2021;218(12):e20211872.
 36. Gibson CJ, Kim HT, Zhao L, et al. Donor clonal hematopoiesis and recipient outcomes after transplantation. *J Clin Oncol*. 2022;40(2):189-201.
 37. Ktena YP, Koldobskiy MA, Barbato MI, et al. Donor T cell DNMT3a regulates alloreactivity in mouse models of hematopoietic stem cell transplantation. *J Clin Invest*. 2022;132(13):e158047.
 38. Flohr Svendsen A, Yang D, Kim K, et al. A comprehensive transcriptome signature of murine hematopoietic stem cell aging. *Blood*. 2021;138(6):439-451.
 39. Sullivan C, Chen Y, Shan Y, et al. Functional ramifications for the loss of P-selectin expression on hematopoietic and leukemic stem cells. *PLoS One*. 2011;6(10):e26246.
 40. Pelletier SD, Hong DS, Hu Y, Liu Y, Li S. Lack of the adhesion molecules P-selectin and intercellular adhesion molecule-1 accelerate the development of BCR/ABL-induced chronic myeloid leukemia-like myeloproliferative disease in mice. *Blood*. 2004;104(7):2163-2171.
 41. Wang T, Xia C, Weng Q, et al. Loss of *Nupr1* promotes engraftment by tuning the quiescence threshold of hematopoietic stem cells via regulation of the p53-checkpoint pathway. *Haematologica*. 2022;107(1):154-166.
 42. Zeng C, Li X, Li A, et al. Knockdown of NUPR1 inhibits the growth of U266 and RPM18226 multiple myeloma cell lines via activating PTEN and caspase activation-dependent apoptosis. *Oncol Rep*. 2018;40(3):1487-1494.
 43. Santofimia-Castaño P, Xia Y, Lan W, et al. Ligand-based design identifies a potent NUPR1 inhibitor exerting anticancer activity via necroptosis. *J Clin Invest*. 2019;129(6):2500-2513.
 44. Toghiani D, Zeng S, Mahammadov E, et al. Myeloid-biased HSC require Semaphorin 4A from the bone marrow niche for self-renewal under stress and life-long persistence. *bioRxiv*. Preprint posted online 12 January 2022. <https://doi.org/10.1101/2022.01.12.476097>
 45. Anderson GSF, Ballester-Beltran J, Giotopoulos G, et al. Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma. *Blood*. 2022;139(16):2471-2482.
 46. Lawson H, van de Lagemaat LN, Barile M, et al. CITED2 coordinates key hematopoietic regulatory pathways to maintain the HSC pool in both steady-state hematopoiesis and transplantation. *Stem Cell Reports*. 2021;16(11):2784-2797.
 47. Mattes K, Berger G, Geugien M, Vellenga E, Schepers H. CITED2 affects leukemic cell survival by interfering with p53 activation. *Cell Death Dis*. 2017;8(10):e3132.
 48. Kruta M, Sunshine MJ, Chua BA, et al. Hsf1 promotes hematopoietic stem cell fitness and proteostasis in response to ex vivo culture stress and aging. *Cell Stem Cell*. 2021;28(11):1950-1965.e6.

49. Dong Q, Xiu Y, Wang Y, et al. HSF1 is a driver of leukemia stem cell self-renewal in acute myeloid leukemia. *Nat Commun*. 2022;13(1):6107.
50. Kourtis N, Lazaris C, Hockemeyer K, et al. Oncogenic hijacking of the stress response machinery in T cell acute lymphoblastic leukemia. *Nat Med*. 2018;24(8):1157-1166.
51. Suo M, Rommelfanger MK, Chen Y, et al. Age-dependent effects of Igf2bp2 on gene regulation, function, and aging of hematopoietic stem cells in mice. *Blood*. 2022;139(17):2653-2665.
52. He X, Li W, Liang X, et al. IGF2BP2 overexpression indicates poor survival in patients with acute myelocytic leukemia. *Cell Physiol Biochem*. 2018;51(4):1945-1956.
53. Desterke C, Bennaceur-Griscelli A, Turhan AG. EGR1 dysregulation defines an inflammatory and leukemic program in cell trajectory of human-aged hematopoietic stem cells (HSC). *Stem Cell Res Ther*. 2021;12(1):419.
54. Min IM, Pietramaggiore G, Kim FS, Passequé E, Stevenson KE, Wagers AJ. The transcription factor EGR1 controls both the proliferation and localization of hematopoietic stem cells. *Cell Stem Cell*. 2008;2(4):380-391.
55. Kulkarni R. Early growth response factor 1 in aging hematopoietic stem cells and leukemia. *Front Cell Dev Biol*. 2022;10:925761.
56. Wang N, Yin J, You N, et al. TWIST1 preserves hematopoietic stem cell function via the CACNA1B/Ca²⁺/mitochondria axis. *Blood*. 2021;137(21):2907-2919.
57. Li H, Wang Y, Pang X, et al. Elevated TWIST1 expression in myelodysplastic syndromes/acute myeloid leukemia reduces efficacy of hypomethylating therapy with decitabine. *Haematologica*. 2020;105(10):e502.
58. Abdelfattah A, Hughes-Davies A, Clayfield L, et al. Gata2 haploinsufficiency promotes proliferation and functional decline of hematopoietic stem cells with myeloid bias during aging. *Blood Adv*. 2021;5(20):4285-4290.
59. Zhang SJ, Ma LY, Huang QH, et al. Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia. *Proc Natl Acad Sci U S A*. 2008;105(6):2076-2081.
60. Wlodarski MW, Collin M, Horwitz MS. GATA2 deficiency and related myeloid neoplasms. *Semin Hematol*. 2017;54(2):81-86.
61. Carpenter RL, Gokmen-Polar Y. HSF1 as a cancer biomarker and therapeutic target. *Curr Cancer Drug Targets*. 2019;19(7):515-524.
62. Saida S, Zhen T, Kim E, et al. Gata2 deficiency delays leukemogenesis while contributing to aggressive leukemia phenotype in Cbfb-MYH11 knockin mice. *Leukemia*. 2020;34(3):759-770.
63. Ho YH, Méndez-Ferrer S. Microenvironmental contributions to hematopoietic stem cell aging. *Haematologica*. 2020;105(1):38-46.
64. Bogeska R, Mikecin A-M, Kaschutnig P, et al. Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging. *Cell Stem Cell*. 2022;29(8):1273-1284.e8.
65. Mitchell CA, Verovskaya EV, Calero-Nieto FJ, et al. Stromal niche inflammation mediated by IL-1 signalling is a targetable driver of haematopoietic ageing. *Nat Cell Biol*. 2023;25(1):30-41.
66. Pietras EM, Mirantes-Barbeito C, Fong S, et al. Chronic interleukin-1 exposure drives haematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal. *Nat Cell Biol*. 2016;18(6):607-618.
67. Kovtonyuk LV, Caiado F, Garcia-Martin S, et al. IL-1 mediates microbiome-induced inflammation of hematopoietic stem cells in mice. *Blood*. 2022;139(1):44-58.
68. Valletta S, Thomas A, Meng Y, et al. Micro-environmental sensing by bone marrow stroma identifies IL-6 and TGFβ1 as regulators of hematopoietic ageing. *Nat Commun*. 2020;11(1):4075.
69. Mei Y, Ren K, Liu Y, et al. Bone marrow-confined IL-6 signaling mediates the progression of myelodysplastic syndromes to acute myeloid leukemia. *J Clin Invest*. 2022;132(17):e152673.
70. Zhang B, Chu S, Agarwal P, et al. Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor-treated CML stem cells. *Blood*. 2016;128(23):2671-2682.
71. Carey A, Edwards Dkt, Eide CA, et al. Identification of interleukin-1 by functional screening as a key mediator of cellular expansion and disease progression in acute myeloid leukemia. *Cell Rep*. 2017;18(13):3204-3218.
72. Krambs JR, Monlish DA, Gao F, Schuettelz LG, Link DC. Microbiota signals suppress B lymphopoiesis with aging in mice. *Front Immunol*. 2021;12:767267.
73. Zeng X, Li X, Li X, et al. Fecal microbiota transplantation from young mice rejuvenates aged hematopoietic stem cells by suppressing inflammation. *Blood*. 2023;141(14):1691-1707.
74. Vicente-Dueñas C, Janssen S, Oldenburg M, et al. An intact gut microbiome protects genetically predisposed mice against leukemia. *Blood*. 2020;136(18):2003-2017.
75. Wang R, Yang X, Liu J, et al. Gut microbiota regulates acute myeloid leukaemia via alteration of intestinal barrier function mediated by butyrate. *Nat Commun*. 2022;13(1):2522.
76. Malard F, Vekhoff A, Lapusan S, et al. Gut microbiota diversity after autologous fecal microbiota transfer in acute myeloid leukemia patients. *Nat Commun*. 2021;12(1):3084.
77. Jeon OH, Mehdipour M, Gil TH, et al. Systemic induction of senescence in young mice after single heterochronic blood exchange. *Nat Metab*. 2022;4(8):995-1006.
78. Ju Z, Jiang H, Jaworski M, et al. Telomere dysfunction induces environmental alterations limiting hematopoietic stem cell function and engraftment. *Nat Med*. 2007;13(6):742-747.
79. Gnani D, Crippa S, Della Volpe L, et al. An early-senescence state in aged mesenchymal stromal cells contributes to hematopoietic stem and progenitor cell clonogenic impairment through the activation of a pro-inflammatory program. *Aging Cell*. 2019;18(3):e12933.
80. Attema JL, Pronk CJH, Norrdahl GL, Nygren JM, Bryder D. Hematopoietic stem cell ageing is uncoupled from p16 INK4A-mediated senescence. *Oncogene*. 2009;28(22):2238-2243.
81. Chang J, Wang Y, Shao L, et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. *Nat Med*. 2016;22(1):78-83.
82. Zhou Y, Xin X, Wang L, et al. Senolytics improve bone forming potential of bone marrow mesenchymal stem cells from aged mice. *NPJ Regen Med*. 2021;6(1):34.
83. Abdul-Aziz AM, Sun Y, Hellmich C, et al. Acute myeloid leukemia induces protumoral p16INK4a-driven senescence in the bone marrow microenvironment. *Blood*. 2019;133(5):446-456.
84. Justesen J, Stenderup K, Ebbesen EN, Mosekilde L, Steiniche T, Kassem M. Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis. *Biogerontology*. 2001;2(3):165-171.
85. Almeida M, Kim HN, Han L, et al. Increased marrow adipogenesis does not contribute to age-dependent appendicular bone loss in female mice. *Aging Cell*. 2020;19(11):e13247.
86. Ambrosi TH, Scialdone A, Graja A, et al. Adipocyte accumulation in the bone marrow during obesity and aging impairs stem cell-based hematopoietic and bone regeneration. *Cell Stem Cell*. 2017;20(6):771-784.e6.
87. Naveiras O, Nardi V, Wenzel PL, Hauschka PV, Fahey F, Daley GQ. Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. *Nature*. 2009;460(7252):259-263.
88. Hu T, Kitano A, Luu V, et al. Bmi1 suppresses adipogenesis in the hematopoietic stem cell niche. *Stem Cell Reports*. 2019;13(3):545-558.
89. Zhou BO, Yu H, Yue R, et al. Bone marrow adipocytes promote the regeneration of

- stem cells and haematopoiesis by secreting SCF. *Nat Cell Biol.* 2017;19(8):891-903.
90. Tucci J, Chen T, Margulis K, et al. Adipocytes provide fatty acids to acute lymphoblastic leukemia cells. *Front Oncol.* 2021;11:665763.
91. Shafat MS, Oellerich T, Mohr S, et al. Leukemic blasts program bone marrow adipocytes to generate a protumoral microenvironment. *Blood.* 2017;129(10):1320-1332.
92. Jones CL, Stevens BM, D'Alessandro A, et al. Inhibition of amino acid metabolism selectively targets human leukemia stem cells. *Cancer Cell.* 2018;34(5):724-740.e4.
93. DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. *N Engl J Med.* 2020;383(7):617-629.
94. Pollyea DA, Stevens BM, Jones CL, et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. *Nat Med.* 2018;24(12):1859-1866.
95. Marlein CR, Zaitseva L, Piddock RE, et al. NADPH oxidase-2 derived superoxide drives mitochondrial transfer from bone marrow stromal cells to leukemic blasts. *Blood.* 2017;130(14):1649-1660.
96. Mistry JJ, Hellmich C, Lambert A, et al. Venetoclax and daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid Leukemia. *Biomark Res.* 2021;9(1):35.
97. Mistry JJ, Moore JA, Kumar P, et al. Daratumumab inhibits acute myeloid leukaemia metabolic capacity by blocking mitochondrial transfer from mesenchymal stromal cells. *Haematologica.* 2021;106(2):589-592.
98. Ho TT, Dellorusso PV, Verovskaya EV, et al. Aged hematopoietic stem cells are refractory to bloodborne systemic rejuvenation interventions. *J Exp Med.* 2021;218(7):e20210223.
99. Ho TT, Warr MR, Adelman ER, et al. Autophagy maintains the metabolism and function of young and old stem cells. *Nature.* 2017;543(7644):205-210.
100. Zaro BW, Noh JJ, Mascetti VL, et al. Proteomic analysis of young and old mouse hematopoietic stem cells and their progenitors reveals post-transcriptional regulation in stem cells. *eLife.* 2020;9:e62210.
101. Mansell E, Sigurdsson V, Deltcheva E, et al. Mitochondrial potentiation ameliorates age-related heterogeneity in hematopoietic stem cell function. *Cell Stem Cell.* 2021;28(2):241-256.e6.
102. Hernández-Malmierca P, Vonficht D, Schnell A, et al. Antigen presentation safeguards the integrity of the hematopoietic stem cell pool. *Cell Stem Cell.* 2022;29(5):760-775.e10.
103. Wattrus SJ, Smith ML, Rodrigues CP, et al. Quality assurance of hematopoietic stem cells by macrophages determines stem cell clonality. *Science.* 2022;377(6613):1413-1419.
104. Porto ML, Rodrigues BP, Menezes TN, et al. Reactive oxygen species contribute to dysfunction of bone marrow hematopoietic stem cells in aged C57BL/6 J mice. *J Biomed Sci.* 2015;22(1):97.
105. Khan AO, Rodriguez-Romera A, Reyat JS, et al. Human bone marrow organoids for disease modelling, discovery and validation of therapeutic targets in hematological malignancies. *Cancer Disco.* 2023;13(2):364-385.

© 2023 by The American Society of Hematology.
Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.